Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
Macrophages sustain tumour progression by facilitating angiogenesis, promoting immunosuppression, and enhancing cancer cell invasion and metastasis. They also modulate tumour response to anti-cancer therapy in pre-clinical models. This knowledge has motivated the development of agents that target tumour-associated macrophages (TAMs), some of which have been investigated in early clinical trials. Here, we provide a comprehensive overview of the biology and therapeutic targeting of TAMs, highlighting opportunities, setbacks, and new challenges that have emerged after a decade of intense translational and clinical research into these multifaceted immune cells. (c) 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Didier Trono, Priscilla Turelli, Evaristo José Planet Letschert, Sandra Eloise Kjeldsen, Filipe Amândio Brandão Sanches Vong Martins, Cyril David Son-Tuyên Pulver, Olga Marie Louise Rosspopoff, Romain Forey, Florian Huber